272BIO

272BIO

Foundation date

19/07/2019

Sector

#Biotechnology - Therapeutics

Subsector

• #Therapeutics - Drug delivery
• #Therapeutics - Proteins
• #Therapeutics - Anti-infectives
• #Therapeutics - Antibodies

Therapeutic areas

• #Digestive system
• #Endocrine - nutritional and metabolic diseases
• #Infectious and parasitic diseases
• #Respiratory system
• #Skin and subcutaneous tissue

272BIO are developing biotherapeutics, using innovative technologies, for livestock and companion animal disorders. Applying novel technologies, we are able to reduce hitherto prohibitive production costs and produce affordable therapies.  VHH antibodies enable 272BIO to design bespoke drugs for optimal disease control.